search
Back to results

Low-dose Combination of Three Antihypertensive Drugs (3D)

Primary Purpose

Arterial Hypertension

Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Tripliam (perindopril, indapamide, amlodipine)
Reaptan (perindopril, amlodipine)
Sponsored by
University of Roma La Sapienza
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Arterial Hypertension focused on measuring arterial hypertension, antihypertensive drugs

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients with arterial hypertension resistant to monotherapy

Exclusion Criteria:

None

Sites / Locations

  • Sapienza University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Three antihypertensive Drugs

Two antihypertensive drugs

Arm Description

Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine

Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine

Outcomes

Primary Outcome Measures

Number of patients who reach target blood pressure
How many patients have blood pressure within normal limits

Secondary Outcome Measures

Full Information

First Posted
March 4, 2016
Last Updated
March 16, 2016
Sponsor
University of Roma La Sapienza
search

1. Study Identification

Unique Protocol Identification Number
NCT02710552
Brief Title
Low-dose Combination of Three Antihypertensive Drugs
Acronym
3D
Official Title
Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
April 2016 (undefined)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
March 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Roma La Sapienza

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study is to compare the efficacy and safety of low-dose combination of three antihypertensive drugs versus fixed high-dose combination of two antihypertensive drugs in arterial hypertension
Detailed Description
The aim of the study is to compare the efficacy and safety of commercially available low-dose combination of three antihypertensive drugs versus commercially available fixed high-dose combination of two antihypertensive drugs in arterial hypertension

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Hypertension
Keywords
arterial hypertension, antihypertensive drugs

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Three antihypertensive Drugs
Arm Type
Active Comparator
Arm Description
Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
Arm Title
Two antihypertensive drugs
Arm Type
Active Comparator
Arm Description
Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
Intervention Type
Drug
Intervention Name(s)
Tripliam (perindopril, indapamide, amlodipine)
Other Intervention Name(s)
Combination of three antihypertensive drugs
Intervention Description
Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
Intervention Type
Drug
Intervention Name(s)
Reaptan (perindopril, amlodipine)
Other Intervention Name(s)
Combination of two antihypertensive drugs
Intervention Description
Fixed combination of perindopril 10 mg and amlodipine 5 mg
Primary Outcome Measure Information:
Title
Number of patients who reach target blood pressure
Description
How many patients have blood pressure within normal limits
Time Frame
From baseline to the end of the 3-month study period

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with arterial hypertension resistant to monotherapy Exclusion Criteria: None
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Francesco Pelliccia, MD
Phone
390649971
Ext
123
Email
md4151@mclink.it
First Name & Middle Initial & Last Name or Official Title & Degree
Cesare Greco, MD
Phone
390649971
Ext
123
Email
md4151@mclink.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlo Gaudio, MD
Organizational Affiliation
Sapienza University
Official's Role
Study Chair
Facility Information:
Facility Name
Sapienza University
City
Rome
ZIP/Postal Code
00161
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Low-dose Combination of Three Antihypertensive Drugs

We'll reach out to this number within 24 hrs